Lantheus Holdings, Inc. (NASDAQ:LNTH) Director David F. Burgstahler sold 230,685 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $17.25, for a total value of $3,979,316.25. Following the completion of the sale, the director now directly owns 13,248 shares of the company’s stock, valued at approximately $228,528. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lantheus Holdings, Inc. (NASDAQ:LNTH) traded up 3.24% during midday trading on Thursday, reaching $17.50. The company’s stock had a trading volume of 808,360 shares. Lantheus Holdings, Inc. has a 1-year low of $7.18 and a 1-year high of $20.45. The company has a market capitalization of $653.63 million, a price-to-earnings ratio of 23.91 and a beta of 0.91. The company’s 50-day moving average price is $17.68 and its 200-day moving average price is $14.99.

Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.18. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The company had revenue of $88.83 million during the quarter, compared to analysts’ expectations of $80.56 million. During the same quarter in the prior year, the business posted $0.24 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. On average, analysts predict that Lantheus Holdings, Inc. will post $1.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/31/david-f-burgstahler-sells-230685-shares-of-lantheus-holdings-inc-lnth-stock.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LNTH. Strategic Wealth Advisors Group LLC acquired a new position in Lantheus Holdings during the second quarter valued at about $594,000. Castleark Management LLC acquired a new position in Lantheus Holdings during the second quarter valued at about $5,936,000. California State Teachers Retirement System acquired a new position in Lantheus Holdings during the second quarter valued at about $815,000. The Manufacturers Life Insurance Company boosted its position in Lantheus Holdings by 547.8% in the second quarter. The Manufacturers Life Insurance Company now owns 23,761 shares of the medical equipment provider’s stock valued at $419,000 after buying an additional 20,093 shares during the last quarter. Finally, State Street Corp boosted its position in Lantheus Holdings by 3,932.8% in the second quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock valued at $10,891,000 after buying an additional 601,714 shares during the last quarter. 84.35% of the stock is owned by institutional investors.

LNTH has been the subject of a number of recent analyst reports. Jefferies Group LLC raised their target price on Lantheus Holdings from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, May 3rd. Zacks Investment Research raised Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $17.00 target price for the company in a report on Thursday, May 4th. Cantor Fitzgerald initiated coverage on Lantheus Holdings in a report on Monday, July 17th. They issued an “overweight” rating and a $22.00 target price for the company. Credit Suisse Group raised their target price on Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Finally, BidaskClub downgraded Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Lantheus Holdings presently has an average rating of “Buy” and a consensus target price of $18.60.

Lantheus Holdings Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Insider Buying and Selling by Quarter for Lantheus Holdings (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.